WW International, Inc.

What they do

Weight Watchers subscriptions are sold across three membership tiers: Core (digital tools including the Points Program, AI Body Scanner and member social network), Core+ (adds unlimited coaching and in-person/virtual workshops plus Menopause and GLP-1 Success Programs), and Med+ (U.S. only, adds board-certified doctors and clinicians trained in obesity medicine and a formulary of FDA-approved medications). The company reports one reportable segment and describes its business as Behavioral (digital subscriptions with optional workshops) and Clinical (Weight Watchers Clinic combined with digital subscriptions and workshops). It has operated for more than sixty years and emerged from Chapter 11 bankruptcy on June 24, 2025.

Revenue drivers

• Behavioral (Core and Core+) — Subscription revenue from digital products, with Core+ adding coaching, workshops and specialized programs; Core+ ended Q2 2026 with 541 thousand subscribers, up 13.9% year-over-year.
• Clinical (Med+, U.S. only) — Subscription revenue through Weight Watchers Clinic providing clinician access and a medication formulary; Clinical subscription revenue was $39.9 million in Q2 2026, up 30.4% year-over-year, with 197 thousand end-of-period clinical subscribers, up 55.7%.
• Subscription pricing and mix (ARPU) — Monthly subscription revenue per average subscriber rose 10.2% year-over-year in Q2 2026, which management attributes to continued mix shift toward Clinical.

Recent performance

Q2 2026 revenue was $162.3 million, with total end-of-period subscribers of 2.5 million, 197 thousand clinical subscribers and 541 thousand Core+ subscribers. Clinical subscription revenue grew 30.4% year-over-year and Core+ subscribers grew 13.9%, with clinical subscribers flat sequentially as the company reduced Clinical marketing spend after elevated Q1 spend. Gross margin was 70.3% (adjusted 73.6%), marketing expense was $47.9 million or 29.5% of revenue, net income was $14.1 million and adjusted EBITDA was $39.8 million. Operating activities generated $24.3 million of cash in the quarter, and the company prepaid $36.8 million of term loan principal, reducing the outstanding principal by $41.4 million and annualized interest expense by about $4 million. Quarterly revenue has declined sequentially from $177.0 million (period ended 2025-06-24) to $172.1 million, $168.3 million and $162.3 million.

Strategy

Management describes 2026 as a year of focused transition and is positioning the company around an integrated Behavioral and Clinical model for the GLP-1 era, including the Med+ tier that provides access to obesity-medicine clinicians and FDA-approved medications. The company is emphasizing its higher-value Core+ Behavioral tier and reported a third consecutive quarter of sequential Core+ subscriber growth, while recalibrating Clinical marketing investment following elevated Q1 2026 spend. It is also reducing debt, prepaying $36.8 million of term loan principal in Q2 2026 and cutting annualized interest expense by roughly $4 million. Following bankruptcy emergence, it changed its fiscal year to end December 31 and applies fresh start accounting.

Risks

• Post-bankruptcy execution and relationships — The company recently emerged from Chapter 11 and cites risks including maintaining relationships with vendors, members, employees and other third parties, negative publicity and retaining key employees.
• Clinical growth comparisons — Q2 2026 Clinical growth was achieved despite lapping significant prior-year growth from the former compounded semaglutide offering, and clinical subscribers were flat sequentially.
• Declining total revenue — Reported quarterly revenue fell from $177.0 million to $162.3 million across recent quarters, and full-year 2026 guidance of $620-$635 million implies continued contraction versus historical levels.
• Leverage and fixed obligations — The balance sheet at June 30, 2026 showed $424.0 million of long-term debt, $561.8 million of total liabilities and $101.5 million of cash, with a $465.0 million term loan maturing June 24, 2030.

Outlook

Management reaffirmed full-year 2026 guidance of $620 million to $635 million of revenue and $105 million to $115 million of adjusted EBITDA. It said the business remains cash accretive after generating positive operating cash flow in Q2 2026 and expressed confidence in building momentum into 2027 and beyond. No other forward figures were provided in the excerpt.